Drugs / 225Ac-PSMA-XT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07135102 | Oct 2024 → Dec 2026 expected | castration-resistant prostate carcinoma | Xiaorong Sun | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-PSMA-XT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07135102 ↗ |
| Known as | PSMA-XT | “225Ac -labeled PSMA ligand(PSMA-XT)” NCT07135102 ↗ |